Wedbush Reiterates Outperform Rating for Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a research note issued on Monday,RTT News reports. They presently have a $11.00 price target on the stock. Wedbush’s price target would indicate a potential upside of 348.98% from the stock’s current price.

Other research analysts have also issued reports about the company. Oppenheimer decreased their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. HC Wainwright began coverage on Perspective Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $10.00 target price for the company. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, Bank of America downgraded Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the company from $24.00 to $5.00 in a research report on Monday, November 25th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $14.56.

Perspective Therapeutics Stock Down 5.8 %

Shares of NYSE CATX opened at $2.45 on Monday. The stock’s fifty day moving average price is $3.10 and its two-hundred day moving average price is $7.02. Perspective Therapeutics has a one year low of $2.32 and a one year high of $19.05.

Hedge Funds Weigh In On Perspective Therapeutics

Large investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Perspective Therapeutics by 221.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock valued at $5,788,000 after purchasing an additional 298,778 shares during the last quarter. State Street Corp increased its stake in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the period. Janus Henderson Group PLC increased its stake in shares of Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after buying an additional 355,685 shares during the period. FMR LLC increased its stake in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares during the period. Finally, BNP Paribas Financial Markets increased its stake in shares of Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company’s stock valued at $635,000 after buying an additional 44,174 shares during the period. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.